All In Biotech

Drug Trial Radar · NCT06327295

A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the

Last checked: Nov 20, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jul 1, 2024

Primary completion

Jun 30, 2025

Study completion Jan 30, 2026

Sponsor

Lead sponsor
AmtixBio Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in participants with mild to moderate onychomycosis

Conditions

  • Onychomycosis

Interventions

  • ATB1651-102- Cohort 1Drug

    Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.

  • ATB1651-102- Cohort 2Drug

    Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 20 weeks with a follow-up for 16 weeks.

  • ATB1651-102- Cohort 3Drug

    Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 twice daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.

  • ATB1651-102- Cohort 4Drug

    Dosage form- Topical solution; Dosage- 5% formulation The participants will apply the daily dose of 5% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.

  • PlaceboDrug

    participants will receive matching placebo across cohorts 1-4 of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the complete cure rate with topical ATB1651 3% and ATB1651 5% in participants with mild to moderate onychomycosis.Time frame: From screening to end of study treatment up to 252 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Zealand Clinical Research Christchurch

    Christchurch, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.